Business
Suda Pharmaceuticals share price soars 200% on TGA approval – Motley Fool Australia
The Suda Pharmaceuticals share price is soaring over 200% following TGA approval for its insomnia treatment product, ZolpiMist.
The Suda Pharmaceuticals Ltd(ASX: SUD) share price has soared 207.4% today, at the time of writing. The surge came following the company’s announcement that its Zolpimist product has been approved by the TGA (Therapeutic Goods Administration). ZolpiMist is an oral spray for the treatment of insomnia.
In an investor presentation released by Suda Pharmaceuticals earlier this month, the company estimated the market for insomnia treatments will be approximately US$4 billion by 2026. Furthermore, a…
-
Business24 hours agoHow to retire in your 50s with ASX shares
-
General24 hours agoFood and garden organic waste bin system on verge of collapse across WA’s South West
-
Noosa News20 hours agoBroncos’ Adam Reynolds confident of NRL finals return, Raiders’ Josh Papalii injured
-
Noosa News21 hours agoRiverfire spectators face crowd crushes, huge delays on trains and buses